Perioperative blood transfusion and ovarian cancer survival rates: A meta-analysis based on univariate, multivariate and propensity score matched data

ObjectiveVaginal hysterectomy with bilateral salpingo-oophorectomy may be an alternative strategy for patients with low-risk endometrial cancer and medical co-morbidities precluding laparoscopic or abdominal procedures. The current study evaluates the prevalence of co-existent ovarian malignancy in patients with endometrial cancer and the influence of bilateral salpingo-oophorectomy on survival outcomes in these patients.MethodsMedline and EMBASE were searched for studies published between January 1, 2000 and November 20, 2017 that investigated (1) the prevalence of co-existing ovarian malignancy (either metastases or primary synchronous ovarian cancer in women with endometrial cancer, and (2) the influence of bilateral salpingo-oophorectomy on recurrence and/or survival rates.ResultsOf the pre-menopausal and post-menopausal patients (n=6059), 373 were identified with metastases and 106 were identified with primary synchronous ovarian cancer. Of the post-menopausal patients (n=6016), 362 were identified with metastases and 44 were identified with primary synchronous ovarian cancer. Survival outcomes did not differ for pre-menopausal patients with endometrial cancer with and without bilateral salpingo-oophorectomy (5-year overall survival rates were 89–94.5% and 86–97.8%, respectively).ConclusionBilateral salpingo-oophorectomy during vaginal hysterectomy seems to have a limited impact on disease outcome in patients with endometrial cancer. These results support the view that vaginal hysterectomy alone or with bilateral salpingo-oophorectomy may be an option for patients with endometrial cancer who are not ideal surgical candidates.

Download Full-text

Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival

Genes Chromosomes and Cancer ◽

10.1002/gcc.20676 ◽

2009 ◽

Vol 48 (8) ◽

pp. 711-724 ◽

Cited By ~ 9

Author(s):

Mads Thomassen ◽

Kirsten M. Jochumsen ◽

Ole Mogensen ◽

Qihua Tan ◽

Torben A. Kruse

Keyword(s):

Gene Expression ◽

Ovarian Cancer ◽

Cancer Survival ◽

Meta Analysis ◽

Ovarian Cancer Survival

Download Full-text

No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies

Current Pharmaceutical Design ◽

10.2174/1381612825666190716113126 ◽

2019 ◽

Vol 25 (23) ◽

pp. 2595-2601

Author(s):

Yongbo Wang ◽

Xiaoxue Liu ◽

Pengfei Yan ◽

Yongyi Bi ◽

Yu Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Cohort Studies ◽

Cancer Patients ◽

Cancer Survival ◽

Meta Analysis ◽

Disease Free Survival ◽

Preliminary Evidence ◽

Hazard Ratios ◽

Retrospective Cohort Studies ◽

Ovarian Cancer Survival

Background: A number of observational studies examined the association between metformin therapy and ovarian cancer survival outcomes, but the results are inconsistent. Objective: The study aimed to investigate the effect of metformin on survival for ovarian cancer patients. Methods: PubMed, Embase and Web of Science databases were searched for relevant studies from the inception to June 11, 2019. The strength of the relationship was assessed using summary of hazard ratios (HRs) with corresponding 95% confidence intervals (CI). Statistical analyses were carried out using the random-effects model. Results: Totally, 6 retrospective cohort studies involving 2,638 ovarian cancer patients were included. Metformin was not associated with improved overall survival (HR=0.78, 95% CI 0.54-1.12, P=0.175, I2= 61.6%) and disease- free survival (HR=0.49, 95% CI 0.20-1.17, P=0.106, I2=82.1%) in ovarian cancer patients compared to nonmetformin users. Conclusion: The current study provides preliminary evidence that metformin may not be associated with a survival benefit for ovarian cancer patients. More studies with rigorous designs are needed.

Download Full-text

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

Journal of Functional Biomaterials ◽

10.3390/jfb10040055 ◽

2019 ◽

Vol 10 (4) ◽

pp. 55

Author(s):

Aneta Cymbaluk-Płoska ◽

Peter Sobolewski ◽

Anita Chudecka-Głaz ◽

Ewa Wiśniewska ◽

Joanna Łapczuk ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Survival ◽

Survival Rates ◽

Double Emulsion ◽

Ovarian Adenocarcinoma ◽

Local Inflammatory Response ◽

Sustained Drug Delivery ◽

Emulsion Process ◽

Ovarian Cancer Survival

Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET-DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity in vitro. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells in vitro. Following intraperitoneal injection in mice, we did not observe adhesions, only mild, clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for the treatment of ovarian cancer.

Download Full-text

Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis

Journal of Cachexia Sarcopenia and Muscle ◽

10.1002/jcsm.12468 ◽

2019 ◽

Vol 10 (6) ◽

pp. 1165-1174 ◽

Cited By ~ 16

Author(s):

Jorne Ubachs ◽

Janine Ziemons ◽

Iris J.G. Minis‐Rutten ◽

Roy F.P.M. Kruitwagen ◽

Jos Kleijnen ◽

...

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Cancer Survival ◽

Meta Analysis ◽

Ovarian Cancer Survival

Download Full-text

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

10.26434/chemrxiv.9911636 ◽

2019 ◽

Author(s):

Aneta Cymbaluk-Płoska ◽

Peter Sobolewski ◽

Anita Chudecka-Głaz ◽

Ewa Wiśniewska ◽

Joanna Łapczuk ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Survival ◽

Survival Rates ◽

Double Emulsion ◽

Ovarian Adenocarcinoma ◽

Local Inflammatory Response ◽

Sustained Drug Delivery ◽

Emulsion Process ◽

Ovarian Cancer Survival

<p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for</p><div><div><div><p>the treatment of ovarian cancer.</p></div></div></div>

Download Full-text

Obesity and Ovarian Cancer Survival: A Systematic Review and Meta-analysis

Cancer Prevention Research ◽

10.1158/1940-6207.capr-12-0048 ◽

2012 ◽

Vol 5 (7) ◽

pp. 901-910 ◽

Cited By ~ 84

Author(s):

Melinda M. Protani ◽

Christina M. Nagle ◽

Penelope M. Webb

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Cancer Survival ◽

Meta Analysis ◽

Ovarian Cancer Survival

Download Full-text

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

10.26434/chemrxiv.9911636.v1 ◽

2019 ◽

Author(s):

Aneta Cymbaluk-Płoska ◽

Peter Sobolewski ◽

Anita Chudecka-Głaz ◽

Ewa Wiśniewska ◽

Joanna Łapczuk ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Survival ◽

Survival Rates ◽

Double Emulsion ◽

Ovarian Adenocarcinoma ◽

Local Inflammatory Response ◽

Sustained Drug Delivery ◽

Emulsion Process ◽

Ovarian Cancer Survival

<div><div><div><p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. We conclude that the developed microencapsulation system could be used for long-term intraperitoneal sustained release of carboplatin for the treatment of ovarian cancer. </p></div></div></div>

Download Full-text

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

10.26434/chemrxiv.9911636.v2 ◽

2019 ◽

Author(s):

Aneta Cymbaluk-Płoska ◽

Peter Sobolewski ◽

Anita Chudecka-Głaz ◽

Ewa Wiśniewska ◽

Joanna Łapczuk ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Survival ◽

Survival Rates ◽

Double Emulsion ◽

Ovarian Adenocarcinoma ◽

Local Inflammatory Response ◽

Sustained Drug Delivery ◽

Emulsion Process ◽

Ovarian Cancer Survival

<p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for</p><div><div><div><p>the treatment of ovarian cancer.</p></div></div></div>

Download Full-text